Dr. Reddy’s Laboratories has confirmed a voluntary licensing agreement with Gilead Sciences for an investigational, once-yearly HIV prevention drug. This announcement clarifies a news item regarding the company obtaining rights to Gilead’s lenacapavir for HIV prevention. The company states this development is correct and aligns with its press release from September 17, 2026. Dr. Reddy’s will be able to leverage this agreement for its product offerings in the HIV prevention space.
Dr. Reddy’s Confirms Licensing Deal for HIV Prevention Drug
Dr. Reddy’s Laboratories Ltd. has officially confirmed a voluntary licensing agreement with Gilead Sciences concerning an investigational, once-yearly drug for HIV prevention. This clarification addresses a news item published on September 17, 2026, titled “Dr Reddy’s gets voluntary license for Gilead’s once-yearly HIV prevention drug.” The company has stated that the information in the news item is correct.
Details of the Agreement
The agreement pertains to Gilead’s investigational drug, lenacapavir, for HIV prevention. Dr. Reddy’s press release on September 17, 2026, titled “Dr. Reddy’s expands collaboration with Gilead Sciences through voluntary licensing agreement for investigational once-yearly lenacapavir for HIV prevention,” accurately reflects the substance of this arrangement. The company has provided assurances that no material event or information requiring immediate disclosure under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been withheld.
Regulatory Compliance
Dr. Reddy’s Laboratories reiterated its commitment to timely disclosures of all material events and information as per the SEBI Listing Regulations. The company has stated that the aforementioned matter does not constitute a material event or information requiring separate disclosure under the said regulations at this stage. They maintain that there is no material event or information that has not been announced to the Exchanges which could explain any unusual movement in trading.
Source: BSE
